Antiviral therapy for COVID-2019

  • Hanik Badriyah Hidayati Neurology Department, Faculty of Medicine, Universitas Airlangga/ Dr. Soetomo General Hospital, Surabaya - Indonesia.
  • Evi Octavia Hospital Pharmacy Installation of Dr. Soetomo General Hospital, Surabaya, East Java, Indonesia.
  • Cempaka Thursina Srisetyaningrum Neurology Department, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta - Indonesia.
DOI: https://doi.org/10.35975/apic.v25i3.1522
Keywords: Antiviral therapy, Drugs, COVID-19

Abstract

The whole world is experiencing a global pandemic caused by Coronavirus disease 2019. As the pandemic progresses, there has been much research on antiviral drugs, such as hydroxychloroquin, chloroquine, remdesivir, lopinavir-ritonavir, favipiravir, oseltamivir, and umifenovir.  Specific antiviral drugs proven to be effective against SARS-CoV-2 have not been found and approved for the medication of COVID-19. Currently, case detection, infection control, monitoring, prevention, and supportive care are the means focused on the treatment of COVID-19. A large scale research is currently underway to analyze safety and efficacy of antiviral drugs, while trials of the SAR-CoV-2 vaccine are rapidly expanding. This mini review briefly introduces the current antiviral therapy for COVID-19.

Key word: Antiviral therapy; Drugs; COVID-19

Citation: Hidayati HB, Octavia E, Srisetyaningrum CT. Antiviral therapy for COVID-2019. Anaesth. pain intensive care 2021;25(3):387–390. DOI: doi.org/10.35975/apic.v25i3.1522

Received: January 8, 2021; Reviewed: March 11, 2021; Accepted: March 11, 2021

Published
06-02-2021
How to Cite
Hidayati, H., Octavia, E., & Srisetyaningrum, C. (2021). Antiviral therapy for COVID-2019. Anaesthesia, Pain & Intensive Care, 25(3), 387–390. https://doi.org/10.35975/apic.v25i3.1522
Issue
Vol 25 No 3 (2021): May-June
Section
Review Article